This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

21 Most Volatile Biopharma Stocks Closing Out 2012

BOSTON ( TheStreet) -- We're less than two months from putting 2012 to bed but an astonishing number of biopharmaceutical firms still have significant stock-moving catalysts that have yet to play out.

Here's an alphabetized list of 21 biotech and drug companies with FDA drug approvals and significant clinical trial results expected before the end of 2012.

Acadia Pharmaceuticals (ACAD - Get Report): Top-line results from a phase III study of pimavanserin in patients with Parkinson's disease psychosis expected in November. Read more on the BioRunUp trade in Acadia and a deeper dive into previous pimavanserin studies.

Alexza Pharmaceuticals' (ALXA) Adasuve, an inhaled formulation of the antipsychotic medication loxapine, is expecting an FDA approval decision on Dec. 21. U.S. regulators have rejected Adasuve twice previously.

When Amarin (AMRN) reports third-quarter results on Thursday, Nov. 8, investors will be listening for an update on Vascepa's New Chemical Entity (NCE) status and plans for the drug's commercial launch.

Amicus Therapeutics (FOLD) and partner GlaxoSmithKline (GSK) will announce top-line results from two phase III studies of migalastat (Amigal) in Fabry disease before the end of the year.

Biogen Idec (BIIB) will complete a busy year of drug development when it announces results from a phase III study of dexpramipexole in amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease. Data expected before end of the year.

Biomarin Pharmaceuticals (BMRN): Phase III study of GALNS for MPS IV also known as Morquio Syndrome before end of year. If the study is successful and the drug is approved, GALNS could double Biomarin's revenue over the next five years

Catalyst Pharmaceutical Partners (CPRX)has promised results from a phase IIb study of CPP-109 (vigabatrin) in cocaine addiction before the middle of November. That means data this week or next.

Celgene (CELG): Top-line results from the phase III study of Abraxane in pancreatic cancer before the end of the year. TheStreet contributor Nate Sadeghi predicts a win for Celgene from this important Abraxane study.

Last May, Celldex Therapeutics (CLDX) reported interim results from a mid-stage study of its targeted cancer drug CDX-011 demonstrating superior response rates in patients with advanced metastatic breast cancer compared to single-agent chemotherapy. Updated results from this study will be presented at the San Antonio Breast Cancer Symposium in December.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ZIOP $12.92 0.00%
ACAD $38.28 0.00%
AMRN $2.07 0.00%
EXEL $5.49 0.00%
HEB $0.13 0.00%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs